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A B S T R A C T
Background: Since the early 1970s therapeutic drugmonitoring (TDM) of anti-epilepsy drug (AED) levels
has been available to assist in the review process of patients with epilepsy. Routine blood levels were not
part of the Quality and Outcomes Framework in the New GP Contract, neither have they been generally
recommended in National Guidelines (NICE and SIGN) for the management of patients with epilepsy.
Aim: To assess the impact of an educational intervention, the New GP Contract and NICE guidelines on
the number of requests for TDM.
Design: Retrospective study.
Setting: 39 general practices serving Chester (13), the Rural area surrounding Chester (13) and Ellesmere
Port (13).
Methods: An educational intervention took place in the individual Chester practices between December
2001 andMarch 2003. For the Rural and Ellesmere Port practices therewas one combined event inMarch
2004 and in March 2007, respectively. Practices were encouraged, not to routinely request TDM, except
in certain circumstances. The number of TDM requests for Chester, Rural and Ellesmere Port were
obtained from the local laboratory in Chester, plus other nearby hospitals, to provide control groups.
Main outcome measures: The number of TDM requests from primary care for Chester, Rural, Ellesmere
Port, Wirral, Crewe, Warrington and Wrexham, April to April, 2002 through to 2008, where available.
Results: There has been a fall in the number requests in all districts. The most signiﬁcant falls were in
Chester (47%), Rural (34%) and Ellesmere Port (47%), and corresponded to the time of their educational
intervention. The fall has been less marked in Wirral (25%), Crewe (27%), Wrexham (10%) and
Warrington (9%). In 2004, the ﬁrst year after the introduction of the New GP Contract, TDM in Chester
and the Rural fell signiﬁcantly, while those in Ellesmere Port, Wirral, Crewe and Wrexham increased.
TDM dropped signiﬁcantly in Ellesmere Port in the year after their educational intervention. Despite the
valproate assay being clinically unhelpful therewere still 611 requests in the areas studied in 2007/2008.
Conclusion: The overall number of TDM requests has fallen since 2004 with the introduction of the New
GP Contract and National Guidelines on the management of patients with epilepsy. The reduction has
been more signiﬁcant in areas where the changes were supplemented by an educational intervention.
PCTs should endeavour to facilitate the introduction of National Guidelines with a supportive
educational process, facilitated by educators with an interest and stake hold in those speciﬁc dillnesses.
There is a signiﬁcant cost to the NHS of inappropriate requests for TDM. Further study is required to
quantify the indications for current requests for TDM.
 2010 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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TDM has been historically recommended as part of the routine
monitoring of patients with epilepsy in Primary care.1,2 However,
inmore recent National Guidelines for themanagement of epilepsy* Corresponding author. Tel.: +44 1244 390396; fax: ++44 1244 370762.
E-mail address: ian.minshall@nhs.net (I. Minshall).
1059-1311/$ – see front matter  2010 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2010.10.037routine TDM was not recommended,3 NICE guidance for the
management of epilepsy was published in October 2004,4 stating
in section 2.8.27.
Indications for monitoring of TDM are:
 detection of non-adherence to the prescribed medication;
 suspected toxicity;
 adjustment of phenytoin dose;
 management of pharmacokinetic interactions;vier Ltd. All rights reserved.
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failure, and pregnancy.
Selective rather than routinemonitoring of TDMwas supported
in a recent Cochrane Database review.5
TDM is useful in speciﬁc clinical setting in which compliance,
toxicity or overdose feature. The determination of serum drug
concentrations can play a valuable role in guiding patient
management provided that the measurements are undertaken
with a clear indication; are interpreted appropriately and taking
into consideration all the clinical details pertaining to the patient.6
In a study in secondary care, only 20% of requests for TDMwere
thought to be appropriate.7
The standard of care of patients with epilepsy in Chester was
recorded as being poor prior to the introduction of the New
Contract in 2004,8 with only 19% of patients having a regular
yearly review, 49% had not been reviewed in the previous year
and 53% of adults who should be receiving shared care are not
doing so.
Epilepsy was included as a quality indicator for the ﬁrst time in
the New GP Contract.9 In the four quality and outcome framework
indicators for epilepsy, TDM was not included.
An educational intervention took place in 13 individual Chester
practices from December 2001 to March 2003, which showed a
signiﬁcant improvement in documentation and review rates of
patients with epilepsy in those practices inﬂuenced by the
intervention. There was an even more marked improvement in
review rates for those practices inﬂuenced by the education and
the introduction of the New Contract.10 The average yearly review
rate for patients with epilepsy in Chester is now 95%.11
2. Methods
Although not part of the original research project, it was
perceived a fall in the number of TDM might be a measure of the
impact of the educational process. Early liaison with the Countess
of Chester Hospital biochemistry laboratory showed there had
indeed been a fall in requests from Chester and the Rural practices.
Therefore a retrospective study to include the introduction of the
New Contract was undertaken.
2.1. Chester practices
An educational interventionwas completed in all practices after
an individual patient audit and an epilepsy review template
completed, the ﬁrst session was in December 2001 and the last
March 2003.
Thiswas a 2 h tutorial (85% attendance of local GPs) inwhichDr.
Smith gave an overview of the diagnosis and management of
epilepsy.
In a section of this talk Dr. Smith indicated that routine TDM
was not required. Especially with valproate, as ‘plasma-valproate
concentrations are not a useful index of efﬁcacy, therefore routineTable 1
Number of TDM requested year on year 2002–2008.
Number of TDM requested year on year from Primary C
2002–2003 2003–2004 2004–
Chester 248 258 209
Rural 145 151 97
Ellesmere Port 212 249 201
Wirral n/a 531 553
Crewe 713 647 732
Warrington n/a n/a 693
Wrexham 250 250 284monitoring is unhelpful’.12 He indicated TDM is useful in the
following circumstances:
 To check for compliance.
 If a patient was apparently toxic, and was on two different drugs
either of which could be causing the toxicity.
 For phenytoin especially with poly-pharmacy and due to its
unusual pharmacokinetics.
2.2. Rural practices
One large educational session took place in March 2004 for all
the practices, in which Dr. Smith repeated the above lecture.
2.3. Ellesmere Port practices
One large educational session took place in March 2007 for all
the practices. Dr. Minshall, now a GPwSI, gave the lecture
2.4. Wirral, Crewe, Warrington and Wrexham practices
No educational events were organised in these areas that has
speciﬁcally included guidance on TDM.
The biochemistry departments at the Countess of Chester
Hospital (Chester, Rural and Ellesmere Port), Arrowe Park Hospital
(Wirral), Leighton Hospital (Crewe), Warrington General Hospital
and Wrexham Maelor Hospital were contacted to provide the
number of requests for TDM over the proceeding years (phenytoin,
phenobarbitone, valproate and carbamazepine. Only two labs
provided lamotrigine levels so these were excluded). These
requests were from Primary Care only, not A&E, hospital inpatient
or outpatient requests, and from April to April, as far back as
records existed.
Statistics were analysed using Microsoft Excel computer
software, using x2 analysis.
3. Results
The following results were obtained from the ﬁve laboratories
for the seven different areas (Table 1).
These are represented graphically as percentage change from
the baseline level for each area, in Fig. 1 for Chester, Rural and
Ellesmere Port, and in Fig. 2 for Wirral, Crewe, Warrington and
Wrexham.
Chester and the Rural practices had their most signiﬁcant fall in
2004/2005, which coincided with the introduction of the New
Contract, NICE guidelines and the educational intervention. The
number of requests has fallen gradually sincewith a slight increase
for the Rural in 2007/2008. In Ellesmere Port there was a increase
in 2004–2006, followed by a signiﬁcant fall in 2007/2008.
In 2004/2005 in Crewe, Wirral and Wrexham there was an
increase in requested levels, after which there has been gradual fall.are
2005 2005–2006 2006–2007 2007–2008
192 134 133
91 78 96
212 171 112
530 411 402
626 585 520
721 787 633
239 219 226
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Fig. 1. Percentage change from baseline in TDM for Chester, Rural, and Ellesmere
Port year on year 2002–2008. Chester education December 2001 to March 2003;
R = Rural educational session March 2004; EP = Ellesmere Port educational session
March 2006.
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Fig. 2. Percentage change from baseline in TDM for Wirral, Crewe, Warrington and
Wrexham year on year 2002–2008.
Table 3
Number of valproate TDM requested year on year 2002-2008.
2002–2003 2003–2004 2004–
Chester 89 74 69
Rural 33 35 18
Ellesmere Port 64 57 52
Wirral n/a 63 72
Crewe 218 238 265
Warrington n/a n/a 238
Wrexham 50 52 54
Total 454 519 768
Table 2
Year on year statistical comparison between different areas.
Year on year comparison
02/03 vs. 03/04 03/04 vs. 04/05
Chester/Rural 1 0.15
Chester/Ellesmere Port 0.35 0.14
Rural/Ellesmere Port 0.46 0.15
Chester/Crewe 0.19 0.0018
Chester/Wirral 0.026
Chester/Warrington
Chester/Wrexham 0.8 0.007
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there has been an increase in requests, until 2007/2008 where the
numbers fell.
The statistical differences are illustrated in Table 2 between the
different areas, each year is compared with the previous year.
Signiﬁcant changes are in bold.
There was no statistical difference between Chester and the
Rural for any year. Compared with these latter two areas, in
Ellesmere Port there was a signiﬁcant fall in 2007/2008.
There were statistically signiﬁcant falls in requests in Chester
compared with Crewe, Wirral, and Wrexham in 2004/2005, and
again in 2006/2007 compared with Crewe and Warrington.
Thenumber of valproate assays is illustrated inTable 3, theﬁgure
in brackets represents the percentage fall or increase from baseline.
Valproate TDM have fallen overall from 2002/2003 to 2007/
2008 by 56% in Chester, Rural and Ellesmere Port. Whereas in the
other four areas there were small decreases in two areas, and
increases in the other two (a fall of 7% overall using baselines from
the differing years). In the only complete set of data from 2002/
2003 through to 2007/2008, Chester/Rural/Ellesmere Port vs.
Crewe/Wrexham, there was a statistically signiﬁcant fall in
requests p = 0.048. If Ellesmere Port, who received their education
later, are excluded, the fall in the number of requests falls
statistically further p = 0.027.
4. Discussion
The New Contract had a signiﬁcant effect on the review rate of
patients with epilepsy. If Primary Care clinicians thought routine
TDM was normal practice, it would be expected the number of
requests to rise. Equally inapopulationofpatients previouslypoorly
cared for, clinical indications may have arisen requiring an assay to
be requested, hence a further possible increase in TDM. In the two
areas, Chester and the Rural, inﬂuenced by education at the time of
the introduction of the New Contract a fall in TDMwas observed. In
all the other areas, including Ellesmere Port, an increase in TDMwas
documented, but in the latter area there was a signiﬁcant fall after
their educational session. Theeffect of the educational input causing
a signiﬁcant fall on two separate occasions implies that a signiﬁcant2005 2005–2006 2006–2007 2007–2008
56 48 38 (57%)
24 25 21 (37%)
49 48 23 (65%)
61 64 66 (101%)
199 175 180 (18%)
259 269 230 (4%)
65 58 53 (106%)
713 687 611
04/05 vs. 05/06 05/06 vs. 06/07 06/07 vs. 07/08
0.84 0.25 0.27
0.33 0.36 0.016
0.48 0.71 0.001
0.49 0.017 0.42
0.72 0.43 0.72
0.25 0.0002 0.107
0.26 0.058 0.76
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routinely, and not for the indications in the guidelines.
The valproate assay was singled out in the educational sessions
as being particularly unhelpful. Therewas a reduction by some 56%
in requests for this TDM in the areas who received the education
compared with the other four areas where there was an overall
reduction of 7% compared with the earliest baseline ﬁgure. These
[()TD$FIG]
Request for Primary Care
Valproate 
Carbamazepine 
Phenytoin 
Phenobarbitone 
Lamotrigine 
Other      
What is the indication for the test? 
Routine: 
Compliance: 
Toxicity suspected: 
Pharmacokinetic interaction: 
Pregnancy: 
Phenytoin: 
Other: 
Routine levels are not usually indicated , do you 
to continue? 
Yes     No 
Dosage:  
Time of sample: 
Time of last dose: 
Clinical data: 
Print form 
Example: John Smith 1/1/1964 
Indication: Compliance  Dru
Dose: 200 bd  Time: 08:00  
Pre-dose TDM  is recommended.   
If a dosage change,  two weeks between samples
is recommended 
Fig. 3. A proposed pathway for AED assay requests on line. * If two drﬁgures support the assumption the educational process had a
major effect on TDM. In 2007/2008 there were still 611 requests
from the seven areas, at a cost of approximately £6 per assay.
It is possible that the overall fall is related to patients being
taken off older drugs and being prescribed more recently
introduced drugs, which do not have TDM recommended as part
of their proﬁle, and local laboratories do not perform assays. AED drug level 
  *
Please note the valproate assay is of  
limited clinical value 
wish 
Exit 
g:  Carbamazepine Date: 1/6/2009 
Time of last dose: 22:00 (31/5/2009) 
  
ugs chosen the system would deal with each request separately.
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control of their seizureswith improvements in their care since QOF
was introduced.
Some variance may have occurred by studying different areas
whichmay have different social groupings and hence prevalence of
epilepsy. However, all the areas except Crewe have visiting
consultants from the Walton Centre for Neurology.
NICE guidelines are excellent and have helped Primary Care to
formalise patient care and referral onto secondary care. The
number of guidelines in all areas has been overwhelming. A co-
ordinated educational program needs to be provided by PCTs to
deliver to GPs, the main, important points from the guidelines as
they are released. This study shows that after an educational
program in Chester, Rural and Ellesmere Port, the number of TDM
fell signiﬁcantly. TDM has fallen in the other areas, albeit slowly,
which perhaps indicates there is a slow uptake of this recommen-
dation in the management of patients with epilepsy.
Requests for blood tests in West Cheshire PCT are done on the
computer and on line. Certain ‘pop up’ warnings and clinical
guidance can appear informing GPs about individual tests.
Information and guidance should be available to inform GPs in
this way, as to when and when not to order TDM, especially
valproate. A short pathway is proposed in Fig. 3.
Further study needs to be undertaken to quantify the
indications for TDM requests and do they meet the criteria
advocated in guidelines, or are they in fact being done as a routine.
This would need the co-operation of GPs documenting more data
on the request form.
5. Conclusion
TDM is not usually required in the routine care of patients with
epilepsy. TDM does not appear in either the New GP Contract QOF
targets or in NICE guidelines in 2004.
There has been a general trend for the number of TDM to fall
since 2004. This fall has been statistically most signiﬁcant in areas
that have received additional education. PCTs should consider their
educational provision when each NICE guideline is published, to
highlight important and practical issues.The continuing unnecessary request for assays has implications
ﬁnancially and on patient care.
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